Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? (Q38032481)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869006%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869006%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869006%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Anna R Carta

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869006%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

7 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869006%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

published in

Neurotoxicity Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869006%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869006%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869006%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

112-123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22869006%20AND%20SRC:MED&resulttype=core&format=json

Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice

10 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Alterations of T-lymphocyte populations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Regulation of Glial Cell Functions by PPAR-gamma Natural and Synthetic Agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Is the answer for Parkinson disease already in the medicine cabinet?: Unfortunately not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Parkinson's disease: mechanisms and models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

ATP mediates rapid microglial response to local brain injury in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Peroxisome proliferator-activated receptors: nuclear control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Be fit or be sick: peroxisome proliferator-activated receptors are down the road

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Non-steroidal anti-inflammatory drugs in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Neuroscience. Brain under surveillance: the microglia patrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Anti-apoptotic actions of PPAR-gamma against ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Unravelling mononuclear phagocyte heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Fate mapping analysis reveals that adult microglia derive from primitive macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Interleukin-6 serum levels in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Microglia: a sensor for pathological events in the CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Phosphatidylinositol 3-kinase-dependent suppression of the human inducible nitric-oxide synthase promoter is mediated by FKHRL1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

The influence of microglia on the pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Interleukin-1β contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Glial reactions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Inflammation and adaptive immunity in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Mitochondria and Programmed Cell Death in Parkinson's Disease: Apoptosis and Beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Microglia in neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Peroxisome proliferator-activated receptors, coactivators, and downstream targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

The myeloid cells of the central nervous system parenchyma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Microglial physiology: unique stimuli, specialized responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Peripheral cytokines profile in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

PPARs and molecular mechanisms of transrepression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Microglial cell origin and phenotypes in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Microglial phenotype: is the commitment reversible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Innate and adaptive immunity for the pathobiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

RAR/RXR and PPAR/RXR Signaling in Spinal Cord Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Targeting programmed cell death in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Interleukin-10 provides direct trophic support to neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-012-9342-7

Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA

21 January 2018

1 reference

12 December 2020

Regulation of Fc receptor and major histocompatibility complex antigen expression on isolated rat microglia by tumour necrosis factor, interleukin-1 and lipopolysaccharide: effects on interferon-gamma induced activation

1 reference

12 December 2020

Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions

1 reference

12 December 2020

Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.

1 reference

12 December 2020

Histochemical detection of apoptosis in Parkinson's disease.

1 reference

12 December 2020

Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study

1 reference

12 December 2020

Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists

1 reference

12 December 2020

Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma

1 reference

12 December 2020

Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis.

1 reference

12 December 2020

Docosahexaenoic acid modulates inflammatory and antineurogenic functions of activated microglial cells

1 reference

12 December 2020

PPAR-gamma agonists as regulators of microglial activation and brain inflammation.

1 reference

12 December 2020

Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease

1 reference

12 December 2020

Toward a functional characterization of blood monocytes

1 reference

12 December 2020

Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

1 reference

12 December 2020

Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.

1 reference

12 December 2020

Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones

1 reference

12 December 2020

Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats

1 reference

12 December 2020

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

1 reference

12 December 2020

Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice

1 reference

12 December 2020

Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease

1 reference

12 December 2020

Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

1 reference

12 December 2020